| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 106 | 2018 | 6550 | 3.220 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 34 | 2009 | 749 | 3.070 |
Why?
|
| Bone Marrow Transplantation | 62 | 2004 | 1581 | 3.000 |
Why?
|
| Hematopoietic Stem Cells | 52 | 2006 | 1242 | 2.790 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 20 | 2011 | 266 | 2.520 |
Why?
|
| Antigens, CD34 | 23 | 2009 | 593 | 1.400 |
Why?
|
| Leukapheresis | 20 | 2009 | 152 | 1.390 |
Why?
|
| Transplantation, Homologous | 52 | 2016 | 2843 | 1.350 |
Why?
|
| Blood Donors | 13 | 2001 | 164 | 1.330 |
Why?
|
| Graft vs Host Disease | 37 | 2018 | 2638 | 1.090 |
Why?
|
| Blood Component Removal | 16 | 2011 | 121 | 0.970 |
Why?
|
| Hematopoiesis | 18 | 2004 | 560 | 0.970 |
Why?
|
| Filgrastim | 23 | 2009 | 191 | 0.970 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 5 | 2011 | 216 | 0.930 |
Why?
|
| Transplantation Conditioning | 23 | 2016 | 2238 | 0.930 |
Why?
|
| Recombinant Proteins | 35 | 2009 | 2927 | 0.900 |
Why?
|
| Tissue Donors | 12 | 2009 | 769 | 0.880 |
Why?
|
| Stem Cell Transplantation | 13 | 2017 | 1360 | 0.800 |
Why?
|
| Cyclophosphamide | 28 | 2016 | 3001 | 0.770 |
Why?
|
| Stem Cells | 6 | 2011 | 1213 | 0.770 |
Why?
|
| Transplantation, Autologous | 40 | 2016 | 1914 | 0.760 |
Why?
|
| Blood Cells | 8 | 2006 | 127 | 0.710 |
Why?
|
| Vidarabine | 15 | 2014 | 1341 | 0.670 |
Why?
|
| Bone Marrow | 24 | 2009 | 2358 | 0.670 |
Why?
|
| Leukemia | 17 | 2002 | 1635 | 0.670 |
Why?
|
| Cell Separation | 13 | 2001 | 612 | 0.640 |
Why?
|
| Lymphoma, Non-Hodgkin | 10 | 2006 | 1039 | 0.610 |
Why?
|
| Immunosuppressive Agents | 13 | 2016 | 1375 | 0.600 |
Why?
|
| Lymphoma | 10 | 2014 | 1467 | 0.580 |
Why?
|
| Blood Transfusion, Autologous | 7 | 2000 | 68 | 0.540 |
Why?
|
| Leukocyte Count | 12 | 2006 | 684 | 0.500 |
Why?
|
| Adult | 105 | 2018 | 77950 | 0.500 |
Why?
|
| Lymphocyte Transfusion | 4 | 2017 | 175 | 0.500 |
Why?
|
| Histocompatibility Testing | 7 | 2018 | 447 | 0.460 |
Why?
|
| Tacrolimus | 7 | 2016 | 335 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 31 | 2018 | 15862 | 0.450 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 9 | 2008 | 2527 | 0.440 |
Why?
|
| Middle Aged | 96 | 2018 | 86204 | 0.430 |
Why?
|
| Leukemia, Myeloid | 6 | 2003 | 941 | 0.430 |
Why?
|
| Etoposide | 13 | 2018 | 870 | 0.420 |
Why?
|
| Humans | 184 | 2018 | 261506 | 0.420 |
Why?
|
| Bone Marrow Cells | 12 | 2003 | 943 | 0.420 |
Why?
|
| Multiple Myeloma | 6 | 2016 | 2138 | 0.420 |
Why?
|
| Antigens, CD | 13 | 2009 | 1385 | 0.410 |
Why?
|
| Graft Survival | 16 | 2018 | 1062 | 0.410 |
Why?
|
| Lymphocyte Subsets | 6 | 2001 | 137 | 0.410 |
Why?
|
| Blood Specimen Collection | 5 | 1999 | 93 | 0.400 |
Why?
|
| Transplantation Chimera | 6 | 2012 | 155 | 0.390 |
Why?
|
| Thalidomide | 2 | 2017 | 569 | 0.380 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 | 2017 | 2390 | 0.370 |
Why?
|
| Male | 104 | 2018 | 123000 | 0.370 |
Why?
|
| Antibodies, Monoclonal | 12 | 2012 | 4367 | 0.360 |
Why?
|
| Bone Marrow Purging | 5 | 2003 | 86 | 0.360 |
Why?
|
| Female | 105 | 2018 | 141928 | 0.360 |
Why?
|
| Neutrophils | 6 | 2012 | 835 | 0.360 |
Why?
|
| Whole-Body Irradiation | 10 | 2006 | 307 | 0.360 |
Why?
|
| Graft vs Host Reaction | 8 | 1998 | 59 | 0.350 |
Why?
|
| Cord Blood Stem Cell Transplantation | 3 | 2012 | 362 | 0.340 |
Why?
|
| Blood Component Transfusion | 4 | 1994 | 89 | 0.320 |
Why?
|
| Cell Fusion | 1 | 2008 | 80 | 0.320 |
Why?
|
| Blood Transfusion | 7 | 1999 | 583 | 0.310 |
Why?
|
| Leukemia, Myeloid, Acute | 20 | 2009 | 6915 | 0.310 |
Why?
|
| Recurrence | 21 | 2015 | 4758 | 0.300 |
Why?
|
| Lymphocyte Depletion | 4 | 2018 | 264 | 0.300 |
Why?
|
| Adolescent | 40 | 2016 | 31252 | 0.290 |
Why?
|
| Combined Modality Therapy | 27 | 2018 | 8865 | 0.290 |
Why?
|
| Erythroid Precursor Cells | 1 | 2006 | 61 | 0.290 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 10 | 2014 | 864 | 0.280 |
Why?
|
| Rituximab | 11 | 2018 | 1528 | 0.280 |
Why?
|
| Remission Induction | 19 | 2013 | 3569 | 0.280 |
Why?
|
| Thiotepa | 5 | 2009 | 118 | 0.280 |
Why?
|
| Busulfan | 7 | 2008 | 764 | 0.280 |
Why?
|
| Melphalan | 10 | 2018 | 834 | 0.280 |
Why?
|
| Leukocytes | 9 | 2004 | 422 | 0.280 |
Why?
|
| Fetal Blood | 3 | 2005 | 482 | 0.270 |
Why?
|
| Neoplastic Stem Cells | 5 | 2002 | 1443 | 0.270 |
Why?
|
| Myelodysplastic Syndromes | 8 | 2009 | 2979 | 0.270 |
Why?
|
| Aged | 46 | 2018 | 70117 | 0.270 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2001 | 1763 | 0.260 |
Why?
|
| Hematologic Neoplasms | 6 | 2018 | 1870 | 0.260 |
Why?
|
| Antineoplastic Agents | 18 | 2009 | 14289 | 0.250 |
Why?
|
| Hodgkin Disease | 8 | 2000 | 1429 | 0.250 |
Why?
|
| Myeloablative Agonists | 5 | 2012 | 384 | 0.250 |
Why?
|
| Acute Disease | 16 | 2018 | 2422 | 0.250 |
Why?
|
| Neovascularization, Physiologic | 1 | 2006 | 345 | 0.250 |
Why?
|
| Third-Party Consent | 1 | 2004 | 27 | 0.240 |
Why?
|
| HLA Antigens | 4 | 2011 | 546 | 0.240 |
Why?
|
| Anemia, Aplastic | 4 | 1999 | 214 | 0.240 |
Why?
|
| Organizational Policy | 1 | 2004 | 73 | 0.230 |
Why?
|
| Cell Differentiation | 8 | 2005 | 4078 | 0.230 |
Why?
|
| Centrifugation, Density Gradient | 4 | 1999 | 124 | 0.230 |
Why?
|
| Models, Biological | 3 | 2011 | 3254 | 0.230 |
Why?
|
| Survival Rate | 20 | 2018 | 12221 | 0.220 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 2004 | 408 | 0.220 |
Why?
|
| T-Lymphocytes | 11 | 2018 | 3869 | 0.220 |
Why?
|
| Photopheresis | 1 | 2003 | 79 | 0.210 |
Why?
|
| Unrelated Donors | 2 | 2016 | 304 | 0.210 |
Why?
|
| Lymphocyte Activation | 7 | 2001 | 1688 | 0.210 |
Why?
|
| Plasma Exchange | 2 | 2007 | 117 | 0.210 |
Why?
|
| Follow-Up Studies | 21 | 2017 | 14889 | 0.200 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 330 | 0.200 |
Why?
|
| Genetic Therapy | 5 | 1996 | 1616 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2018 | 1664 | 0.200 |
Why?
|
| Ifosfamide | 4 | 2009 | 344 | 0.200 |
Why?
|
| Blood Cell Count | 7 | 2012 | 225 | 0.200 |
Why?
|
| Wound Healing | 2 | 2004 | 815 | 0.200 |
Why?
|
| Treatment Outcome | 30 | 2018 | 32848 | 0.200 |
Why?
|
| Methotrexate | 8 | 2006 | 999 | 0.200 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2012 | 37 | 0.190 |
Why?
|
| Cryoglobulinemia | 1 | 2000 | 20 | 0.190 |
Why?
|
| Tissue Engineering | 1 | 2003 | 269 | 0.190 |
Why?
|
| Regeneration | 1 | 2003 | 279 | 0.190 |
Why?
|
| Ethics, Medical | 1 | 2004 | 442 | 0.190 |
Why?
|
| Endothelial Cells | 1 | 2006 | 1048 | 0.180 |
Why?
|
| Immunosorbent Techniques | 4 | 1996 | 57 | 0.180 |
Why?
|
| Models, Theoretical | 1 | 2004 | 785 | 0.180 |
Why?
|
| Cyclosporine | 2 | 1997 | 278 | 0.180 |
Why?
|
| Philadelphia Chromosome | 3 | 2000 | 793 | 0.180 |
Why?
|
| Infectious Mononucleosis | 1 | 1999 | 33 | 0.180 |
Why?
|
| Cryopreservation | 3 | 1999 | 175 | 0.170 |
Why?
|
| Neutropenia | 3 | 2004 | 968 | 0.170 |
Why?
|
| Transduction, Genetic | 4 | 1996 | 475 | 0.170 |
Why?
|
| Child | 26 | 2011 | 29154 | 0.170 |
Why?
|
| Yttrium Radioisotopes | 2 | 2018 | 178 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2000 | 588 | 0.170 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 891 | 0.170 |
Why?
|
| Time Factors | 20 | 2014 | 12926 | 0.170 |
Why?
|
| Drug Administration Schedule | 8 | 2008 | 3472 | 0.170 |
Why?
|
| Survival Analysis | 15 | 2016 | 9180 | 0.170 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 1998 | 25 | 0.170 |
Why?
|
| Epithelial Cells | 2 | 2005 | 1818 | 0.160 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2013 | 713 | 0.160 |
Why?
|
| Treatment Failure | 3 | 2011 | 1391 | 0.160 |
Why?
|
| Bone Marrow Diseases | 2 | 1997 | 177 | 0.160 |
Why?
|
| Graft Rejection | 5 | 2011 | 834 | 0.160 |
Why?
|
| HLA-DR Antigens | 3 | 2004 | 173 | 0.160 |
Why?
|
| Disease-Free Survival | 14 | 2018 | 10001 | 0.160 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 764 | 0.160 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 82 | 0.160 |
Why?
|
| Myocardial Infarction | 2 | 2005 | 1374 | 0.160 |
Why?
|
| Antigens, Differentiation | 3 | 2006 | 238 | 0.160 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1997 | 8 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2000 | 349 | 0.150 |
Why?
|
| Monocytes | 5 | 2004 | 788 | 0.150 |
Why?
|
| Megakaryocytes | 1 | 1998 | 104 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 1999 | 242 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1991 | 709 | 0.150 |
Why?
|
| Colony-Forming Units Assay | 12 | 2003 | 249 | 0.150 |
Why?
|
| Cytarabine | 8 | 2018 | 1973 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2001 | 1299 | 0.150 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1997 | 156 | 0.150 |
Why?
|
| Safety | 4 | 2002 | 465 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 2 | 2002 | 1350 | 0.140 |
Why?
|
| Radioactive Hazard Release | 1 | 1996 | 5 | 0.140 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2016 | 129 | 0.140 |
Why?
|
| Lymphoma, Follicular | 3 | 2012 | 587 | 0.140 |
Why?
|
| Culture Media | 1 | 1996 | 319 | 0.140 |
Why?
|
| Rhodamines | 1 | 1995 | 49 | 0.130 |
Why?
|
| Colony-Stimulating Factors | 3 | 1990 | 82 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2001 | 2796 | 0.130 |
Why?
|
| Retrospective Studies | 18 | 2016 | 37905 | 0.130 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2007 | 105 | 0.130 |
Why?
|
| Liver | 2 | 2002 | 2961 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 2 | 1996 | 442 | 0.130 |
Why?
|
| Histocompatibility | 4 | 2001 | 168 | 0.130 |
Why?
|
| Hyperglycemia | 1 | 1997 | 333 | 0.130 |
Why?
|
| Drug Resistance, Multiple | 1 | 1995 | 204 | 0.130 |
Why?
|
| Risk Factors | 10 | 2018 | 17523 | 0.120 |
Why?
|
| Growth Substances | 3 | 1990 | 300 | 0.120 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 73 | 0.120 |
Why?
|
| Immunophenotyping | 5 | 2001 | 1681 | 0.120 |
Why?
|
| Carmustine | 4 | 2018 | 214 | 0.120 |
Why?
|
| Cytokines | 4 | 1999 | 2809 | 0.120 |
Why?
|
| Mitoxantrone | 6 | 1995 | 216 | 0.120 |
Why?
|
| Platelet Count | 4 | 2001 | 490 | 0.120 |
Why?
|
| Child, Preschool | 15 | 2003 | 16273 | 0.120 |
Why?
|
| Blood Preservation | 6 | 1980 | 54 | 0.120 |
Why?
|
| Bone and Bones | 1 | 1997 | 619 | 0.120 |
Why?
|
| Granulocytes | 6 | 1998 | 224 | 0.120 |
Why?
|
| Gene Amplification | 1 | 2016 | 731 | 0.120 |
Why?
|
| Animals | 23 | 2011 | 59536 | 0.110 |
Why?
|
| SOXC Transcription Factors | 1 | 2013 | 53 | 0.110 |
Why?
|
| Antilymphocyte Serum | 5 | 2009 | 228 | 0.110 |
Why?
|
| Freezing | 10 | 1986 | 59 | 0.110 |
Why?
|
| Kinetics | 2 | 2006 | 2049 | 0.110 |
Why?
|
| Testosterone | 1 | 1997 | 619 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 1993 | 128 | 0.100 |
Why?
|
| Chronic Disease | 4 | 2003 | 1819 | 0.100 |
Why?
|
| Neoplasms | 7 | 2002 | 15193 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 361 | 0.100 |
Why?
|
| Idarubicin | 3 | 2000 | 446 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1999 | 1756 | 0.100 |
Why?
|
| Blood Platelets | 3 | 2012 | 731 | 0.100 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 2011 | 38 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 641 | 0.100 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 666 | 0.100 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 204 | 0.100 |
Why?
|
| Feasibility Studies | 5 | 2016 | 2292 | 0.100 |
Why?
|
| Magnetics | 1 | 1991 | 107 | 0.100 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1990 | 167 | 0.090 |
Why?
|
| Microspheres | 1 | 1991 | 210 | 0.090 |
Why?
|
| Allografts | 3 | 2018 | 650 | 0.090 |
Why?
|
| Thrombocytopenia | 3 | 2007 | 846 | 0.090 |
Why?
|
| Leukemia, Lymphoid | 2 | 1988 | 276 | 0.090 |
Why?
|
| Radiation Injuries | 2 | 1996 | 1411 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 2488 | 0.090 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1990 | 115 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 1005 | 0.090 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1990 | 186 | 0.090 |
Why?
|
| Incidence | 4 | 2002 | 5673 | 0.090 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 3 | 1999 | 111 | 0.090 |
Why?
|
| Benzylamines | 1 | 2009 | 105 | 0.090 |
Why?
|
| Endocrine System Diseases | 1 | 1989 | 83 | 0.080 |
Why?
|
| Anemia, Hemolytic | 2 | 2007 | 53 | 0.080 |
Why?
|
| Injections, Subcutaneous | 2 | 2006 | 334 | 0.080 |
Why?
|
| Methylprednisolone | 2 | 1997 | 193 | 0.080 |
Why?
|
| Pilot Projects | 4 | 2000 | 2803 | 0.080 |
Why?
|
| Young Adult | 8 | 2018 | 21445 | 0.080 |
Why?
|
| Heterocyclic Compounds | 1 | 2009 | 119 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 2 | 1986 | 767 | 0.080 |
Why?
|
| Radiotherapy | 1 | 1996 | 1824 | 0.080 |
Why?
|
| Bone Neoplasms | 2 | 1998 | 2576 | 0.080 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1987 | 295 | 0.080 |
Why?
|
| Chimera | 2 | 1995 | 145 | 0.080 |
Why?
|
| Antibodies | 1 | 2011 | 838 | 0.080 |
Why?
|
| Hypertension | 1 | 1997 | 1503 | 0.080 |
Why?
|
| Y Chromosome | 2 | 2002 | 77 | 0.080 |
Why?
|
| Graft vs Tumor Effect | 3 | 2008 | 139 | 0.080 |
Why?
|
| Neuroblastoma | 2 | 1997 | 686 | 0.080 |
Why?
|
| Prospective Studies | 7 | 2016 | 12873 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2009 | 1546 | 0.080 |
Why?
|
| Genetic Markers | 2 | 1995 | 974 | 0.080 |
Why?
|
| CD3 Complex | 3 | 1999 | 314 | 0.080 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 1999 | 122 | 0.080 |
Why?
|
| Prognosis | 10 | 2018 | 21713 | 0.070 |
Why?
|
| Hospital Costs | 2 | 2001 | 228 | 0.070 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2007 | 102 | 0.070 |
Why?
|
| CD8 Antigens | 3 | 2001 | 170 | 0.070 |
Why?
|
| Headache | 2 | 1999 | 163 | 0.070 |
Why?
|
| Antigens, CD20 | 2 | 2006 | 206 | 0.070 |
Why?
|
| Leukocytosis | 2 | 1997 | 112 | 0.070 |
Why?
|
| Equipment Design | 2 | 2002 | 1204 | 0.070 |
Why?
|
| Reference Values | 3 | 1998 | 1099 | 0.070 |
Why?
|
| Vincristine | 2 | 2009 | 1511 | 0.070 |
Why?
|
| Thy-1 Antigens | 2 | 1996 | 51 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1989 | 624 | 0.070 |
Why?
|
| Autografts | 2 | 2018 | 165 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 2 | 2001 | 233 | 0.070 |
Why?
|
| Abdominal Neoplasms | 1 | 1988 | 231 | 0.070 |
Why?
|
| Alkaline Phosphatase | 2 | 1996 | 207 | 0.070 |
Why?
|
| Flow Cytometry | 4 | 2004 | 3033 | 0.070 |
Why?
|
| Breast Neoplasms | 3 | 2000 | 15694 | 0.070 |
Why?
|
| Dexamethasone | 2 | 2009 | 1450 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 663 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2008 | 1294 | 0.070 |
Why?
|
| Cell Survival | 4 | 2003 | 3045 | 0.070 |
Why?
|
| Collateral Circulation | 1 | 2005 | 59 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 1996 | 299 | 0.070 |
Why?
|
| Centrifugation | 3 | 2002 | 66 | 0.070 |
Why?
|
| Leukopenia | 3 | 1997 | 151 | 0.060 |
Why?
|
| Thoracic Neoplasms | 1 | 1988 | 337 | 0.060 |
Why?
|
| Salvage Therapy | 3 | 1997 | 2054 | 0.060 |
Why?
|
| Coronary Circulation | 1 | 2005 | 253 | 0.060 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2003 | 134 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 2232 | 0.060 |
Why?
|
| Membrane Fusion | 1 | 2004 | 51 | 0.060 |
Why?
|
| Blast Crisis | 2 | 1999 | 557 | 0.060 |
Why?
|
| Central Nervous System Diseases | 1 | 2005 | 129 | 0.060 |
Why?
|
| Podophyllotoxin | 2 | 1999 | 63 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2009 | 3005 | 0.060 |
Why?
|
| History, 20th Century | 2 | 1996 | 574 | 0.060 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1988 | 489 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1990 | 7702 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 1995 | 4053 | 0.060 |
Why?
|
| Ischemia | 1 | 2006 | 391 | 0.060 |
Why?
|
| Gamma Rays | 1 | 2004 | 242 | 0.060 |
Why?
|
| Interleukin-2 | 4 | 1991 | 842 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1986 | 366 | 0.060 |
Why?
|
| Immunotoxins | 1 | 2003 | 117 | 0.060 |
Why?
|
| Cell Movement | 2 | 2003 | 2466 | 0.050 |
Why?
|
| HL-60 Cells | 1 | 2003 | 302 | 0.050 |
Why?
|
| Registries | 3 | 2001 | 2170 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 1988 | 610 | 0.050 |
Why?
|
| Dogs | 7 | 1979 | 1155 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2004 | 1869 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 615 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2003 | 133 | 0.050 |
Why?
|
| Uveitis | 1 | 2002 | 33 | 0.050 |
Why?
|
| Pluripotent Stem Cells | 1 | 2003 | 123 | 0.050 |
Why?
|
| Cause of Death | 2 | 2018 | 752 | 0.050 |
Why?
|
| Cells, Cultured | 5 | 2004 | 5637 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2006 | 649 | 0.050 |
Why?
|
| Digestive System | 1 | 2002 | 114 | 0.050 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 324 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 269 | 0.050 |
Why?
|
| Drug Resistance | 3 | 1995 | 587 | 0.050 |
Why?
|
| Keratitis | 1 | 2002 | 102 | 0.050 |
Why?
|
| Hematocrit | 1 | 2002 | 142 | 0.050 |
Why?
|
| Living Donors | 1 | 2002 | 171 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2594 | 0.050 |
Why?
|
| Radiation Injuries, Experimental | 2 | 1979 | 82 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1248 | 0.050 |
Why?
|
| Fibrinogens, Abnormal | 1 | 2000 | 5 | 0.050 |
Why?
|
| Cryoglobulins | 1 | 2000 | 14 | 0.050 |
Why?
|
| Steroids | 1 | 2003 | 356 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 1998 | 4557 | 0.050 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1980 | 24 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2002 | 313 | 0.050 |
Why?
|
| Blood Group Incompatibility | 1 | 1980 | 34 | 0.050 |
Why?
|
| Informed Consent | 1 | 2004 | 419 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 1981 | 139 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 741 | 0.050 |
Why?
|
| Karyotyping | 1 | 2002 | 1022 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2001 | 699 | 0.050 |
Why?
|
| Retroviridae | 2 | 1995 | 332 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 543 | 0.050 |
Why?
|
| Data Collection | 1 | 2002 | 620 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2005 | 574 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 486 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 2173 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 1999 | 64 | 0.040 |
Why?
|
| Drug Evaluation | 3 | 1990 | 425 | 0.040 |
Why?
|
| Necrosis | 1 | 2000 | 580 | 0.040 |
Why?
|
| CD56 Antigen | 1 | 1999 | 83 | 0.040 |
Why?
|
| Haplotypes | 2 | 2012 | 856 | 0.040 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 1989 | 88 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2000 | 829 | 0.040 |
Why?
|
| Diploidy | 2 | 1995 | 114 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 582 | 0.040 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1980 | 238 | 0.040 |
Why?
|
| Plasmapheresis | 2 | 1994 | 61 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 895 | 0.040 |
Why?
|
| Tissue Preservation | 4 | 1986 | 30 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 1995 | 1586 | 0.040 |
Why?
|
| Macrophages | 3 | 1990 | 1304 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2004 | 1085 | 0.040 |
Why?
|
| Biomarkers, Tumor | 4 | 2018 | 10331 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 1998 | 77 | 0.040 |
Why?
|
| Digestive System Diseases | 1 | 1997 | 35 | 0.040 |
Why?
|
| Ploidies | 1 | 1998 | 248 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2011 | 9244 | 0.040 |
Why?
|
| Daunorubicin | 2 | 1995 | 301 | 0.040 |
Why?
|
| Contraindications | 1 | 1997 | 150 | 0.040 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 1996 | 33 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 1999 | 354 | 0.040 |
Why?
|
| Thyrotropin | 1 | 1997 | 119 | 0.040 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1996 | 47 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 830 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 1073 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 1945 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 452 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 7548 | 0.040 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 1996 | 141 | 0.040 |
Why?
|
| Hyperkalemia | 1 | 1997 | 79 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2016 | 141 | 0.040 |
Why?
|
| Uric Acid | 1 | 1996 | 75 | 0.040 |
Why?
|
| Skin | 1 | 2002 | 1259 | 0.030 |
Why?
|
| Cladribine | 1 | 1997 | 233 | 0.030 |
Why?
|
| Body Weight | 1 | 2001 | 1293 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1997 | 193 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 306 | 0.030 |
Why?
|
| Transplantation Immunology | 1 | 1996 | 97 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 148 | 0.030 |
Why?
|
| Antigens, CD19 | 1 | 1999 | 577 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2011 | 334 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 1996 | 185 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2009 | 10035 | 0.030 |
Why?
|
| Radiotherapy Dosage | 3 | 2009 | 3842 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2016 | 6100 | 0.030 |
Why?
|
| Interleukin-3 | 1 | 1995 | 96 | 0.030 |
Why?
|
| Fluorescence | 1 | 1995 | 195 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 665 | 0.030 |
Why?
|
| Azacitidine | 1 | 2001 | 1149 | 0.030 |
Why?
|
| Hemoglobins | 1 | 1996 | 477 | 0.030 |
Why?
|
| Pediatrics | 1 | 2004 | 1141 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2014 | 107 | 0.030 |
Why?
|
| Nausea | 1 | 1996 | 525 | 0.030 |
Why?
|
| Infant | 6 | 1997 | 13310 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 2315 | 0.030 |
Why?
|
| Biopsy | 1 | 2002 | 3443 | 0.030 |
Why?
|
| Biological Transport | 1 | 1995 | 597 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2003 | 7222 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2008 | 1382 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 1997 | 406 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6207 | 0.030 |
Why?
|
| Patient Compliance | 1 | 1997 | 667 | 0.030 |
Why?
|
| Analgesics | 1 | 1996 | 390 | 0.030 |
Why?
|
| Biological Factors | 2 | 1990 | 45 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1996 | 716 | 0.030 |
Why?
|
| Forecasting | 1 | 1996 | 694 | 0.030 |
Why?
|
| Base Sequence | 4 | 1999 | 4917 | 0.030 |
Why?
|
| Burkitt Lymphoma | 2 | 1986 | 335 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 1995 | 1033 | 0.030 |
Why?
|
| Ovarian Neoplasms | 2 | 2000 | 4638 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 621 | 0.030 |
Why?
|
| Langerhans Cells | 1 | 2002 | 50 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1996 | 945 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 1995 | 560 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2011 | 37 | 0.030 |
Why?
|
| Seizures | 1 | 1997 | 989 | 0.030 |
Why?
|
| Cold Temperature | 2 | 1984 | 121 | 0.030 |
Why?
|
| Sex Factors | 1 | 1997 | 2139 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 980 | 0.030 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 119 | 0.030 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1991 | 33 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 29902 | 0.020 |
Why?
|
| Quality Control | 1 | 1993 | 457 | 0.020 |
Why?
|
| Mice | 4 | 2004 | 34495 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2003 | 4938 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 1995 | 889 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1996 | 1694 | 0.020 |
Why?
|
| Calcium | 1 | 1997 | 1537 | 0.020 |
Why?
|
| Pentostatin | 1 | 1990 | 119 | 0.020 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 1995 | 505 | 0.020 |
Why?
|
| Patient Care Team | 1 | 1996 | 795 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1997 | 929 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 1999 | 3203 | 0.020 |
Why?
|
| Haploidy | 1 | 2009 | 40 | 0.020 |
Why?
|
| Rats | 3 | 1984 | 6086 | 0.020 |
Why?
|
| Isoantigens | 1 | 2009 | 62 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 1997 | 739 | 0.020 |
Why?
|
| Fatigue | 1 | 1996 | 1239 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2002 | 6869 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2012 | 598 | 0.020 |
Why?
|
| Menstruation Disturbances | 1 | 1989 | 22 | 0.020 |
Why?
|
| Suspensions | 1 | 1989 | 17 | 0.020 |
Why?
|
| Libido | 1 | 1989 | 40 | 0.020 |
Why?
|
| Ovarian Diseases | 1 | 1989 | 54 | 0.020 |
Why?
|
| Clinical Trials as Topic | 3 | 1990 | 3719 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 1960 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 1995 | 1656 | 0.020 |
Why?
|
| Dextrans | 2 | 1979 | 90 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1999 | 6089 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 899 | 0.020 |
Why?
|
| Carcinoma | 1 | 2000 | 2578 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1989 | 284 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 2008 | 60 | 0.020 |
Why?
|
| Platelet Transfusion | 2 | 2001 | 156 | 0.020 |
Why?
|
| Paclitaxel | 1 | 1995 | 1996 | 0.020 |
Why?
|
| In Vitro Techniques | 3 | 2003 | 1618 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 1988 | 284 | 0.020 |
Why?
|
| Pain | 1 | 1996 | 1658 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1988 | 266 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 114 | 0.020 |
Why?
|
| Age Factors | 1 | 1996 | 5377 | 0.020 |
Why?
|
| Anthraquinones | 1 | 1986 | 27 | 0.020 |
Why?
|
| Tissue Survival | 1 | 1986 | 15 | 0.020 |
Why?
|
| Methods | 1 | 1986 | 189 | 0.020 |
Why?
|
| Clone Cells | 2 | 1985 | 555 | 0.020 |
Why?
|
| Interleukins | 1 | 1988 | 325 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2005 | 110 | 0.020 |
Why?
|
| Family | 1 | 2009 | 736 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1988 | 726 | 0.020 |
Why?
|
| Anemia | 1 | 1991 | 689 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1987 | 363 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2004 | 55 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 1985 | 139 | 0.020 |
Why?
|
| Mechlorethamine | 1 | 1984 | 51 | 0.020 |
Why?
|
| Photosensitivity Disorders | 1 | 1984 | 23 | 0.020 |
Why?
|
| Cell Count | 1 | 2005 | 508 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2004 | 88 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 1988 | 548 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1991 | 1506 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 1323 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 272 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1994 | 218 | 0.010 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 2003 | 21 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2008 | 1021 | 0.010 |
Why?
|
| fas Receptor | 1 | 2004 | 185 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 573 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2003 | 231 | 0.010 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2003 | 83 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 1301 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 1226 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1984 | 503 | 0.010 |
Why?
|
| Immunity | 1 | 2004 | 342 | 0.010 |
Why?
|
| Pyrimidinones | 1 | 1984 | 314 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2005 | 747 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2004 | 403 | 0.010 |
Why?
|
| Rabbits | 2 | 1980 | 957 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 2 | 1980 | 52 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 905 | 0.010 |
Why?
|
| Cyclosporins | 1 | 1981 | 112 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1980 | 79 | 0.010 |
Why?
|
| Mesna | 1 | 2000 | 65 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2004 | 1519 | 0.010 |
Why?
|
| Immunotherapy | 2 | 1994 | 3341 | 0.010 |
Why?
|
| Metaphase | 1 | 2000 | 107 | 0.010 |
Why?
|
| Brachytherapy | 1 | 1987 | 977 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1981 | 173 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2000 | 275 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1979 | 38 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1979 | 83 | 0.010 |
Why?
|
| Plastics | 1 | 1980 | 93 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1980 | 383 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 1479 | 0.010 |
Why?
|
| United States | 1 | 1996 | 15433 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1979 | 153 | 0.010 |
Why?
|
| Lethal Dose 50 | 1 | 1978 | 32 | 0.010 |
Why?
|
| Europe | 2 | 1991 | 649 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 4988 | 0.010 |
Why?
|
| Probability | 1 | 1999 | 866 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1988 | 5112 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1977 | 153 | 0.010 |
Why?
|
| Phenotype | 1 | 1989 | 6295 | 0.010 |
Why?
|
| Infection Control | 1 | 1979 | 270 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1977 | 101 | 0.010 |
Why?
|
| Patient Selection | 1 | 2004 | 2055 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 1989 | 5542 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 1995 | 175 | 0.010 |
Why?
|
| Heart Failure | 1 | 1988 | 2516 | 0.010 |
Why?
|
| Immune Complex Diseases | 1 | 1994 | 12 | 0.010 |
Why?
|
| Staphylococcal Protein A | 1 | 1994 | 18 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 1399 | 0.010 |
Why?
|
| Filtration | 1 | 1994 | 92 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 5047 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1995 | 869 | 0.010 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 1994 | 67 | 0.010 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1994 | 69 | 0.010 |
Why?
|
| Transfusion Reaction | 1 | 1994 | 102 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1977 | 1234 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 4971 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 1991 | 276 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1994 | 402 | 0.010 |
Why?
|
| Germany, West | 1 | 1990 | 1 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1990 | 119 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1994 | 398 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 1989 | 31 | 0.010 |
Why?
|
| HLA-D Antigens | 1 | 1989 | 32 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1989 | 47 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 7591 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 1989 | 86 | 0.010 |
Why?
|
| Premedication | 1 | 1989 | 135 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1989 | 295 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1989 | 235 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1979 | 2967 | 0.010 |
Why?
|
| Pelvis | 1 | 1990 | 362 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1989 | 309 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1995 | 5395 | 0.000 |
Why?
|
| Cisplatin | 1 | 1995 | 2432 | 0.000 |
Why?
|
| Gene Expression | 1 | 1995 | 3570 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1979 | 2992 | 0.000 |
Why?
|
| Preservation, Biological | 1 | 1986 | 15 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1989 | 1008 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1985 | 132 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1995 | 6150 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1991 | 4298 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1989 | 1146 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1986 | 2084 | 0.000 |
Why?
|
| Transplantation, Isogeneic | 1 | 1978 | 56 | 0.000 |
Why?
|
| Temperature | 1 | 1977 | 506 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1983 | 4849 | 0.000 |
Why?
|